EUVIMEDEUVIMED entdecken
Crossref

Economic Evaluation of Molnopyravir, Paxlovid and Fluvoxamine in Treatment of COVID-19 Patients in Iran

Pedram Nourizadeh Tehrani, Mobarakeh Alipanah Dolatabad, Rajabali Daroudi

Iranian Journal of Health Insurance · 01.03.2024 · 6 (4) · 288-299

DOI: 10.66224/ihio.6.4.288 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Iranian Journal of Health Insurance, online erschienen am 01.03.2024. Verfasst von Pedram Nourizadeh Tehrani und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Tehrani, P. N., Dolatabad, M. A., & Daroudi, R. (2024). Economic Evaluation of Molnopyravir, Paxlovid and Fluvoxamine in Treatment of COVID-19 Patients in Iran. Iranian Journal of Health Insurance, 6(4), 288-299. https://doi.org/10.66224/ihio.6.4.288

Vancouver

Tehrani PN, Dolatabad MA, Daroudi R. Economic Evaluation of Molnopyravir, Paxlovid and Fluvoxamine in Treatment of COVID-19 Patients in Iran. Iranian Journal of Health Insurance. 2024;6(4):288-299. doi:10.66224/ihio.6.4.288

BibTeX
@article{Tehrani2024,
  author = {Tehrani, Pedram Nourizadeh and Dolatabad, Mobarakeh Alipanah and Daroudi, Rajabali},
  title = {Economic Evaluation of Molnopyravir, Paxlovid and Fluvoxamine in Treatment of COVID-19 Patients in Iran},
  journal = {Iranian Journal of Health Insurance},
  year = {2024},
  volume = {6},
  number = {4},
  pages = {288--299},
  doi = {10.66224/ihio.6.4.288}
}
Kostenlos starten →